SINGH PHARMA LIMITED

Company Registration Number:
06071342 (England and Wales)

Unaudited abridged accounts for the year ended 29 February 2024

Period of accounts

Start date: 24 February 2023

End date: 29 February 2024

SINGH PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 29 February 2024

Balance sheet
Notes

SINGH PHARMA LIMITED

Balance sheet

As at 29 February 2024


Notes

2024

2023


£

£
Fixed assets
Intangible assets: 3 500,000 500,000
Tangible assets: 4 8,820 10,376
Investments: 5 39,920 39,920
Total fixed assets: 548,740 550,296
Current assets
Stocks: 76,321 71,045
Debtors: 6 705,872 732,551
Cash at bank and in hand: 161,152 262,258
Total current assets: 943,345 1,065,854
Creditors: amounts falling due within one year: 7 (654,481) (769,057)
Net current assets (liabilities): 288,864 296,797
Total assets less current liabilities: 837,604 847,093
Total net assets (liabilities): 837,604 847,093
Capital and reserves
Called up share capital: 4 4
Profit and loss account: 837,600 847,089
Shareholders funds: 837,604 847,093

The notes form part of these financial statements

SINGH PHARMA LIMITED

Balance sheet statements

For the year ending 29 February 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 08 November 2024
and signed on behalf of the board by:

Name: G Singh
Status: Director

The notes form part of these financial statements

SINGH PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 29 February 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

SINGH PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 29 February 2024

2. Employees

2024 2023
Average number of employees during the period 11 10

SINGH PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 29 February 2024

3. Intangible Assets

Total
Cost £
At 24 February 2023 500,000
At 29 February 2024 500,000
Net book value
At 29 February 2024 500,000
At 23 February 2023 500,000

SINGH PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 29 February 2024

4. Tangible Assets

Total
Cost £
At 24 February 2023 49,211
At 29 February 2024 49,211
Depreciation
At 24 February 2023 38,835
Charge for year 1,556
At 29 February 2024 40,391
Net book value
At 29 February 2024 8,820
At 23 February 2023 10,376

SINGH PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 29 February 2024

5. Fixed investments

NBV at 29/02/24 = £39,920 NBV at 23/02/23 = £39,920

SINGH PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 29 February 2024

6. Debtors

2024 2023
££
Debtors due after more than one year: 705,872 732,551

SINGH PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 29 February 2024

7. Creditors: amounts falling due within one year note

at 29/02/24 Bank Loans Overdrafts = £258,892 Trade Creditors = £266,597 Tax = £16,048 Others = £112,944 Total = £654,481 at 23/02/23 Bank Loans Overdrafts = £320,260 Trade Creditors = £220,959 Tax = £36,339 Others = £191,499 Total = £769,057